BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 10731113)

  • 1. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
    Dixon JM; Love CD; Renshaw L; Bellamy C; Cameron DA; Miller WR; Leonard RC
    Endocr Relat Cancer; 1999 Jun; 6(2):227-30. PubMed ID: 10731113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
    Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
    Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
    Miller WR; Dixon JM; Cameron DA; Anderson TJ
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):103-7. PubMed ID: 11850213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
    Dixon JM; Jackson J; Renshaw L; Miller WR
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
    Miller WR; Stuart M; Sahmoud T; Dixon JM
    Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
    Mouridsen H; Gershanovich M
    Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
    Roseman BJ; Buzdar AU; Singletary SE
    J Surg Oncol; 1997 Nov; 66(3):215-20. PubMed ID: 9369969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors and inactivators in breast cancer.
    Lønning PE
    BMJ; 2001 Oct; 323(7318):880-1. PubMed ID: 11668120
    [No Abstract]   [Full Text] [Related]  

  • 13. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    Kijima I; Itoh T; Chen S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
    Smith IE
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):289-93. PubMed ID: 14623523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A decade of letrozole: FACE.
    O'Shaughnessy J
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitors in early breast cancer treatment.
    Mauriac L; Smith I
    Semin Oncol; 2003 Aug; 30(4 Suppl 14):46-57. PubMed ID: 14513436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors in early breast cancer therapy.
    Smith IE
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):9-14. PubMed ID: 15719596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should aromatase inhibitors replace tamoxifen?
    Drug Ther Bull; 2003 Aug; 41(8):57-9. PubMed ID: 12966738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.